Formycon AG announces licensing agreements for Eylea biosimilar FYB203 commercialization in Australia and Latin America
I'm PortAI, I can summarize articles.
Formycon AG has announced that Klinge Biopharma GmbH has signed exclusive licensing agreements with Actor Pharmaceuticals for Australia and Megalabs S.A. for Latin America regarding the commercialization of Formycon’s Eylea® biosimilar FYB203. Klinge will receive upfront and milestone payments, along with royalties on net sales, while Formycon will manage the supply chain and receive additional service payments. This strategic move enhances Formycon's market presence in these regions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments